Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Mary Nalan

Physician Assistant Decatur, AL Physician Assistant

NPI 1588318026 CMS profile 11347961

1310 14Th Ave Se, Decatur, AL 35601

Open in the dashboard

General payments

$3,395

144 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary Nalan of Decatur, AL is reported in the CMS Open Payments database as having received $3,395 across 144 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,541 56
2024 General $953 45
2023 General $901 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Nalan
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Mary Nalan were reported at $1,541. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Mary Nalan Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $901 $167 $52–$557 $160
2024 $953 $178 $55–$600 $164
2025 $1,541 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $491 15 payments
  2. Seattle Genetics, Inc. $255 14 payments
  3. Novartis Pharmaceuticals Corporation $198 11 payments
  4. Janssen Scientific Affairs, LLC $197 2 payments
  5. Pfizer Inc. $180 9 payments
  6. BeOne Medicines USA, Inc. $144 8 payments
  7. AbbVie, Inc. $139 7 payments
  8. Janssen Biotech, Inc. $130 5 payments
  9. Lilly USA, LLC $127 6 payments
  10. Geron Corporation $125 1 payment
  11. Other $1,409 66 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $3,331 142 payments
  2. Education $64 2 payments
Products named General payments · program years 2023–2025
  1. RYBREVANT $242 5 payments
  2. TALVEY $228 3 payments
  3. TUKYSA $225 11 payments
  4. TECVAYLI $197 2 payments
  5. IMBRUVICA $183 10 payments
  6. CALQUENCE $178 4 payments
  7. IMFINZI $174 9 payments
  8. BRUKINSA $148 8 payments
  9. AKEEGA $144 1 payment
  10. ERLEADA $144 1 payment
  11. Other $2,678 123 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

206

Median for Physician Assistant: 241

Drug cost

$18,016

Median for Physician Assistant: $4,110

Branded share of claims

26.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 24 $15,298
Ondansetron Odt Ondansetron Brand 20 $726
Valacyclovir Valacyclovir Hcl Brand 11 $461
Hydroxyurea Generic 20 $364
Omeprazole Generic 22 $262
Mirtazapine Generic 18 $209
Anastrozole Generic 14 $155
Morphine Sulfate Generic 11 $145
Metoclopramide Hcl Generic 24 $126
Promethazine Hcl Generic 12 $121

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 130 billing codes

Paid by Medicare

$437,961

Of which drugs: $386,359

Medicare patients

284

Average age 76

Services billed

39,866

163 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 41%
Cancer 39%
Chronic kidney disease 36%
Ischemic heart disease 35%
COPD 33%
Depression 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 13 900 $18,772
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg J1454 Office 11 19 $10,263
Injection, fluorouracil, 500 mg J9190 Office 14 181 $449
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 21 334 $30
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 22 31 $29
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 15 24 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Fabhalta
  • Novartis Pharmaceuticals Corporation $58
$58 — —
Orserdu
  • Stemline Therapeutics Inc. $46
$46 — —
KRAZATI
  • E.R. Squibb & Sons, L.L.C. $25
  • Mirati Therapeutics, Inc. $20
$46 — —
JAKAFI
  • Incyte Corporation $45
$45 — —
BRUKINSA
  • BeiGene USA, Inc. $41
$41 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

144 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record